Drug profile · INN
zilucoplan
ZILBRYSQ
zilucoplan (ZILBRYSQ) is a complement c5 inhibitor.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L04) L04AJ06
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — zilucoplan
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.83
Quick answer
zilucoplan (ZILBRYSQ) is a complement c5 inhibitor.
Key facts
INN zilucoplan
Brand ZILBRYSQ
Mechanism Complement C5 inhibitor
Target Complement C5
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AJ06
Mechanism of action
Complement C5 inhibitor
Primary target: Complement C5
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is zilucoplan?
zilucoplan (ZILBRYSQ) is a complement c5 inhibitor.
What is the brand name for zilucoplan?
ZILBRYSQ is a marketed brand name for zilucoplan. Check FDA Drugs@FDA for the current US label holder and prescribing information.